Midafotel

Drug Profile

Midafotel

Alternative Names: D-CPPene; SDZ EAA 494

Latest Information Update: 19 Jul 2010

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Novartis
  • Developer BTG; Novartis
  • Class
  • Mechanism of Action Glutamate receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Brain injuries; Cognition disorders; Epilepsy

Most Recent Events

  • 19 Jul 2010 Discontinued - Phase-I for Cognition disorders in Switzerland (unspecified route)
  • 19 Jul 2010 Discontinued - Phase-III for Brain injuries in Switzerland (unspecified route)
  • 20 May 1999 D-CPPene is now called Midafotel
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top